CIRI Opens Coronavirus Clinical Trials
The CHI Institute for Research and Innovation (CIRI) has opened two clinical trials for treatment of patients with COVID-19 at CHI Franciscan St. Joseph Medical Center in Tacoma, WA:
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
The primary objective of this study is to evaluate the efficacy of two remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
The primary objective of this study is to evaluate the efficacy of two remdesivir (RDV) regimens compared to standard of care (SOC), with respect to the time to discharge in participants with moderate coronavirus disease (COVID-19).
For more information, please contact Diana Morales or Conchita Purchase.
Understanding Vaccine Hesitancy in Communities of Color
MAR 04, 2021CommonSpirit Health’s Alisahah Cole, MD, System Vice President Innovation and Policy Population Health, shares insights on why vaccine hesitancy may be more prevalent in communities of color.
The Impact of COVID-19 in Communities of Color
MAR 04, 2021Why are minority communities disproportionately impacted by COVID-19? Initial research indicates that socioeconomic factors are the primary contributor for the increased rate in minority communities.
U.S. COVID-19 cases surpass 18 million
DEC 29, 2020Dr. Thomas McGinn, executive vice president of Physician Enterprise, discussed the current state of the pandemic, the vaccine rollout, and growth in virtual care.